Navigation Links
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Date:11/19/2009

BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.

Dr. Hidvegi stated from his office in Budapest, Hungary:

"The Biropharma claim that research on Avemar does not apply to AveULTRA, www.aveultra.com, is misleading. Avemar has always been manufactured according to methods which I developed and patented. American BioSciences utilizes processes covered by my most recent pending patent. State of the art technology more precisely controls process times and temperatures creating a better quality fermented wheat germ extract. Independent analysis shows that Avemar made by Biropharma and sold under the brand name Ave(TM) and Avemar made by American BioSciences and sold under the brand name AveULTRA, are virtually identical, confirmed by the technique of HPLC finger printing. Furthermore, independent comparison by biological assays in both cell lines and animal models shows the American BioSciences product has superior effects," he said. According to Dr. Hidvegi, these data are being prepared for publication in a peer-reviewed scientific journal.

AveULTRA, newly introduced by American BioSciences, contains the same amount of Avemar fermented wheat germ actives per daily use packet as Ave and is three times more concentrated, with 99 percent less non-active ingredients and no sugar. AveULTRA supports cell metabolic regulation, promotes immune system modulation, and maintains healthy cellular and humoral (Th1/Th2) immune balance. It promotes optimal NK cell targeting ability and the coordinated response of macrophages, B-cells and T-Cells.

"AveULTRA is a huge improvement over the original Ave," said Cincinnati OB/GYN Maureen Pelletier, MD, CCN. "My patients like the concentrated formula, as well as the improved taste."

For more information, contact Dean Draznin Communications, Inc.

SOURCE American BioSciences


'/>"/>
SOURCE American BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
2. Viron to Present Data from Phase II Trial at American Heart Association Conference
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. American Oriental Bioengineering Announces September Investor Conferences Participation
9. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):